Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders for Zevra Therapeutics, Inc., held on June 4, 2026. The filing details the voting outcomes for director elections, auditor ratification, and a proposed charter amendment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Out of 59,114,850 shares outstanding, 46,326,616 shares (78.37%) were voted. The outcomes were as follows:
- Proposal 1 (Election of Directors): Approved. Douglas W. Calder and Corey Watton were elected as Class II directors.
- Proposal 2 (Auditor Ratification): Approved. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Board Declassification): Failed. The proposal to amend the Charter to phase out the classified Board structure and move to annual elections did not receive the required affirmative vote of more than 66 2/3% of outstanding common stock.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk disclosures beyond the standard context of the failed charter amendment. The failure of Proposal 3 indicates continued shareholder support for the current classified Board structure.
Key Facts for Investor Verification
- Verify the specific vote percentages for the failed Proposal 3 to understand the margin of defeat.
- Confirm the terms of the newly elected directors (Calder and Watton) and their tenure until the 2029 annual meeting.
- Review the Definitive Proxy Statement (filed April 20, 2026) for detailed rationale regarding the board structure and director qualifications.
- Note that the company remains a classified Board structure following the vote.